The University of Southampton
University of Southampton Institutional Repository

A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer

A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
When chemotherapy is used in androgen-independent prostate cancer (AIPC), androgen deprivation is continued despite its failure. In this study, we investigated whether it was possible to re-induce hormone sensitivity in previously castrate patients by stopping endocrine therapy during chemotherapy. A phase II prospective study investigated the effects of reintroduction of endocrine therapy after oral chemotherapy in 56 patients with AIPC, which was given without concurrent androgen deprivation. After chemotherapy, patients were given maximum androgen blockade until failure when treatment was switched to diethylstilbestrol and dexamethasone. Patients had already received these endocrine treatments in the same sequence before chemotherapy. All patients were castrate at the start of chemotherapy. Forty-three subsequently restarted endocrine therapy after the completion of chemotherapy. The median overall survival for these 43 patients from the time of restarting endocrine therapy was 7.7 months (95% confidence interval (CI): 3.7–10.9 months). Sixteen (37%) patients had a 50% PSA response to treatment, which was associated with improved overall survival (14.0 months vs 3.7 months P=0.003). Eight out of 12 patients who did not respond to diethylstilbestrol before chemotherapy did so post chemotherapy. Re-induction of hormone sensitivity can occur after chemotherapy in AIPC
re-induction, endocrine sensitivity, prostate cancer, chemotherapy
0007-0920
22-24
Shamash, J.
2f9ac91c-a972-45a6-9d37-10bd37259daa
Davies, A.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Ansell, W.
3b14fc9d-7ca6-4c8e-a84c-2dff45a2ee34
McFaul, S.
96e6ea50-7228-4dd3-853c-3cfd10391289
Wilson, P.
7171df7c-46e3-4f3b-ac2d-ae5bd0458dac
Oliver, T.
56993a04-99df-4e28-b80d-886abc7b5d37
Powles, T.
0d3f760a-49dd-46f1-b94d-abb7d0b9ae6d
Shamash, J.
2f9ac91c-a972-45a6-9d37-10bd37259daa
Davies, A.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Ansell, W.
3b14fc9d-7ca6-4c8e-a84c-2dff45a2ee34
McFaul, S.
96e6ea50-7228-4dd3-853c-3cfd10391289
Wilson, P.
7171df7c-46e3-4f3b-ac2d-ae5bd0458dac
Oliver, T.
56993a04-99df-4e28-b80d-886abc7b5d37
Powles, T.
0d3f760a-49dd-46f1-b94d-abb7d0b9ae6d

Shamash, J., Davies, A., Ansell, W., McFaul, S., Wilson, P., Oliver, T. and Powles, T. (2008) A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. British Journal of Cancer, 98 (1), 22-24. (doi:10.1038/sj.bjc.6604051).

Record type: Article

Abstract

When chemotherapy is used in androgen-independent prostate cancer (AIPC), androgen deprivation is continued despite its failure. In this study, we investigated whether it was possible to re-induce hormone sensitivity in previously castrate patients by stopping endocrine therapy during chemotherapy. A phase II prospective study investigated the effects of reintroduction of endocrine therapy after oral chemotherapy in 56 patients with AIPC, which was given without concurrent androgen deprivation. After chemotherapy, patients were given maximum androgen blockade until failure when treatment was switched to diethylstilbestrol and dexamethasone. Patients had already received these endocrine treatments in the same sequence before chemotherapy. All patients were castrate at the start of chemotherapy. Forty-three subsequently restarted endocrine therapy after the completion of chemotherapy. The median overall survival for these 43 patients from the time of restarting endocrine therapy was 7.7 months (95% confidence interval (CI): 3.7–10.9 months). Sixteen (37%) patients had a 50% PSA response to treatment, which was associated with improved overall survival (14.0 months vs 3.7 months P=0.003). Eight out of 12 patients who did not respond to diethylstilbestrol before chemotherapy did so post chemotherapy. Re-induction of hormone sensitivity can occur after chemotherapy in AIPC

Text
6604051 - Version of Record
Download (105kB)

More information

Published date: 8 January 2008
Keywords: re-induction, endocrine sensitivity, prostate cancer, chemotherapy

Identifiers

Local EPrints ID: 73253
URI: http://eprints.soton.ac.uk/id/eprint/73253
ISSN: 0007-0920
PURE UUID: bd0b088c-cfe0-49b2-93a2-5d746a9c9e63
ORCID for A. Davies: ORCID iD orcid.org/0000-0002-7517-6938

Catalogue record

Date deposited: 04 Mar 2010
Last modified: 14 Mar 2024 02:54

Export record

Altmetrics

Contributors

Author: J. Shamash
Author: A. Davies ORCID iD
Author: W. Ansell
Author: S. McFaul
Author: P. Wilson
Author: T. Oliver
Author: T. Powles

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×